Jason Valentine

Associate
Full contact info

Passions

Science

Family

Endurance Sports

Experience

MapLight Therapeutics Closes Oversubscribed $225 Million Series C

November 3, 2023

Cooley advised MapLight Therapeutics, a clinical-stage biopharmaceutical company, on its oversubscribed $225 million Series C financing.

Read more

Related contacts

Christian Plaza
Partner, Reston
Matthew Schwee
Partner, Reston
David Brinton
Associate, Washington, DC
Michael Tuscan
Partner, Washington, DC
Jim Fulton
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Jason Valentine
Associate, Washington, DC
Cortney Smith
Senior Paralegal, Reston
Jeffery Wyzykowski
Patent Agent, Washington, DC
Dou Yeon Youn
Patent Agent, New York
Zhipeng Zheng
Patent Agent, Washington, DC

Related Practices & Industries

Abivax Announces $235.8 Million IPO

October 20, 2023

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Read more

Related contacts

Div Gupta
Partner, New York
Marc Recht
Partner, Boston
Ryan Sansom
Partner, Boston
Denny Won
Partner, San Francisco
Aaron Pomeroy
Partner, Colorado
Richard Segal
Partner, New York
Nyron J. Persaud
Partner, New York
Madhuri Roy
Partner, Palo Alto
Courtney Thorne
Partner, Boston
Elizabeth Anne Wright
Partner, Brussels
Xander Lee
Partner, Los Angeles Santa Monica
Phil Mitchell
Partner, New York
Stephanie Gentile
Partner, New York
Kevin King
Partner, Washington, DC
Katie Kazem
Partner, Reston
Natasha Leskovsek
Of Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Randy Sabett
Special Counsel, Washington, DC
Jennifer Shanley
Special Counsel, New York
Reid Hooper
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Minkyu Park
Associate, New York
Jesse Schulman
Associate, Washington, DC
Barry Kuang
Associate, Boston
Olivia Creser
Associate, New York
Peter A. Haddad
Associate, San Diego
Samuel Paullin
Associate, Chicago
Evan Leitner
Associate, New York
Rick Jantz
Associate, Los Angeles Santa Monica
Cara Buchicchio
Associate, New York
Jason Valentine
Associate, Washington, DC
Jessica Koffel
Associate, Brussels
Mor Agam
Associate, New York
Cathy Rude
Paralegal Specialist, Boston

Related Practices & Industries

Obsidio Acquired by Boston Scientific

August 18, 2022

Cooley advised Obsidio in the development of its patent portfolio and in defending intellectual property diligence in its acquisition by global medical device company Boston Scientific. Obsidio’s Food and Drug Administration-cleared gel embolic material (GEM) technology is a semisolid material packaged in a ready-to-use form. The GEM technology was developed for embolization, a procedure that blocks blood vessels by using particles to stop bleeding or halt the flow of blood to a tumor or abnormal area of tissue.

“This acquisition strengthens our interventional oncology and embolization portfolio with a differentiated solution for physicians and their patients suffering from hemorrhages, cancer and other debilitating conditions,” said Peter Pattison, president of interventional oncology and embolization at Boston Scientific.

Related contacts

Scott Talbot
Partner, Reston
Jason Valentine
Associate, Washington, DC

Related Practices & Industries